Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The Changing Economic Value and Leverage of Arthroplasty Surgeons

Richard Iorio, MD *
Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA

Article history:
Received 3 November 2021
Received in revised form 7 March 2022
Accepted 8 March 2022
Available online 12 March 2022

Keywords:
IPO rule
RUC
ASC
HOPD
SDD
COVID-19

ARTICLE INFO

This symposium examined the changing economic value and leverage of orthopedic surgeons as total joint arthroplasty (TJA) cases continue to shift from being primarily performed as hospital inpatient only to hospital outpatient and ultimately to ambulatory surgery centers (ASC). Using 100% MedicarePart A and B claims data for the country, this symposium presented the following trends:

- From 2017 to 2021, arthroplasty cases were being performed less frequently as inpatients, and increasingly as outpatients in hospital outpatient departments (HOPD) and ASCs.
- Due to the changes brought about by the removal of TJA from the Inpatient Only List, hospital reimbursement for TJA for the first time has trended lower. Additionally, due to decreases in reimbursement brought about by regulatory changes at the Relative Value Scale Update Committee (RUC), these changes have negatively impacted surgeon income as well. These trends over time of decreasing revenue per case, which varies by care setting, have begun to impact the value of arthroplasty surgeons to hospitals.
- As total professional fees and facility fees generated by arthroplasty surgeons continue to decrease, a projection of how this trend will likely continue prospectively based on the expected continued migration of site of surgery to the outpatient setting has implications on the hospital employment of arthroplasty surgeons in the future.
- Hospitals and health systems are changing compensation for employed surgeons in response to the decrease in revenue per arthroplasty case. Hospitals are experiencing lower profitability due to declining arthroplasty revenue, and thus, there is an increased emphasis on cost reduction regarding arthroplasty cases. This has profound implications on innovation, implant cost, and employed surgeon salary expectations [1].

Discussion

Hospitals have done very well over the 2019 to 2021 time period (Fig. 1). It remains to be seen whether more hospitals will participate in gainsharing or co-management arrangements with their aligned and nonaligned surgeons in order to encourage retaining cases at the hospital rather than having them done in a nonaligned surgery center. Hospitals and hospital systems continue to
consolidate (Fig. 2). The shift of arthroplasty volume (especially non-CMS beneficiaries) to nonaligned ASCs is potentially damaging to the hospital-surgeon relationship (Fig. 3). This is likely to negatively affect the trend of increasing hospital employment of arthroplasty surgeons. It is likely that hospitals, aligned physicians, implant vendors, and ASCs will develop new strategies to control costs and optimize care delivery under the evolving regulatory environment [2].

Dramatic shifts in demand, capacity, and site of service have impacted TJA volumes and revenues over the 2019-21 time period. Other factors impacting arthroplasty care delivery include nursing and perioperative staffing challenges (Fig. 4); we are modifying surgical and procedural schedules to align with current staffing and capacity issues. Analytics are being applied to inform how best to reduce the impact on inpatient capacity while taking care of patients safely, optimize the site of care, and most importantly, ensure
timely interventions for patients’ health situations. Our population is aging, and this trend will continue to preserve the demand for arthroplasty services (Fig. 5). However, hospital systems are consolidating, and that may limit the opportunity for arthroplasty surgeons (Fig. 6).

The understanding of how the IPO rule, Merit-Based Incentive Payment System (MIPS), Alternative Payment Models (such as episode-based arthroplasty bundles and disease management longitudinal bundles), and the RUC reimbursement and coding changes affect orthopedic arthroplasty practices is critical to financial survival in this rapidly changing environment. The shift in emphasis from intervention-based reimbursement to cognitive-based reimbursement has profound implications for orthopedic surgeons. Ambulatory and outpatient care will continue to grow in

![United States Ambulatory Surgery Center Volume](image1)

![United States Nursing Vacancy Rates](image2)
importance (Fig. 7). We need to assert our control as the primary providers of musculoskeletal care in order to have a role in the future disease-based population management models for care delivery [3].

**Conclusions**

The shift to value-based care (VBC) is happening slowly, but the pace seems to be accelerating. CMS and managed care have been
increasingly looking for ways to change the incentives in the healthcare system away from fee for service toward the fee for value.

With health systems and investment groups (Managed Care Organizations, Venture Capital, and hospitals alike) acquiring physician groups and increasingly taking on risk or entering into capitation agreements, we are seeing this shift accelerate. VBC will have significant impacts on the industry, but given that healthcare tends to be evolutionary rather than revolutionary, the change will take some time.

Fig. 7. Inpatient vs Outpatient Hospital Revenues in the United States.

References
[1] Bank of America Global Research. Health Care Facilities Hospital Primer – Everything you need to know about the $1.4T industry. Charlotte, NC: Bank of America; 2021. 12:05AM EDT.
[2] Iorio R, Peavy PR, Keyes D, Dempsey S, McCready DO, Kang JD. Improving arthroplasty efficiency and quality through concentrating service volume by complexity: surviving the Medicare policy changes. J Arthroplasty 2021;36:3055–9. https://doi.org/10.1016/j.arth.2021.04.005.
[3] Skeehan CD, Ortiz D, Sicat CS, Iorio R, Slover J, Bosco J. The 2021 CMS fee schedule’s impact on adult reconstruction surgeon productivity and reimbursement. J Arthroplasty 2021;36:3381–7. https://doi.org/10.1016/j.arth.2021.06.004.